Pharmaceuticals News and Research

RSS

BioClinica offers streamlined electronic transport solutions with the acquisition of CardioNow

BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired the CardioNow unit of Agfa HealthCare.

From Clario 1 Sep 2009

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement”) with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.

1 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS.

1 Sep 2009

Biovail announces Phase III trial results for pimavanserin

Biovail Corporation today announced top-line results from ACADIA Pharmaceutical Inc.’s first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP.

1 Sep 2009

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

LTS LOHMANN Therapie-Systeme AG, the leading developer and manufacturer of transdermal, topical and oral systems with facilities in Andernach, Germany and West Caldwell, New Jersey, celebrates its 25th anniversary.

1 Sep 2009

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

1 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Cumberland Pharmaceuticals to discuss its recently approved FDA product at the UBS Conference

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the UBS Global Life Sciences Conference in New York at 11:00 a.m. Eastern Time on Monday, September 21, 2009. Mr. Kazimi will provide an update on the Company and its Caldolor product, which Cumberland is preparing to launch following its recent approval by the Food and Drug Administration.

1 Sep 2009

New gene therapy vector developed for transferring therapeutic DNA to a cell's nucleus

A research report featured on the cover of the September 2009 print issue of The FASEB Journal describes how Australian scientists developed a new gene therapy vector that uses the same machinery that viruses use to transport their cargo into our cells. As a result of this achievement, therapeutic DNA can be transferred to a cell's nucleus far more efficiently than in the past, raising hopes for more effective treatment of genetic disorders and some types of cancers.

1 Sep 2009

Chemists design polymer-coated nanorods for drug manufacturers

Nanoparticles combining platinum and gold act as superefficient catalysts, but chemists have struggled to create them in an industrially useful form. Rice University chemists have answered the call this week with a polymer-coated version of gold-platinum nanorods, the first catalysts of their kind that can be used in the organic solvents favored by chemical and drug manufacturers.

1 Sep 2009

Managing costs for clinical trials is a big challenge

In the drug industry, clinical trials carry price tags that run well into the tens of millions of dollars. Managing such costs demands a sure hand, and trial sponsors go to great lengths to monitor and manage funds allocated to vendors.

1 Sep 2009

BioSyent's subsidiary BioSyent Pharma signs an exclusive product development agreement

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division.

1 Sep 2009

FDA approves Hospira's six new vial presentations of heparin

Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.

1 Sep 2009

New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

Cytovance Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Dr. Jeffrey Su as Vice President of Bioanalytical Development to its diverse and growing scientific staff. Dr. Su will head up the state of the art Bioanalytical Development laboratory supporting existing and new client needs.

1 Sep 2009

New chief strategy officer for Merkle

Merkle (www.merkleinc.com), one of the nation’s largest and fastest growing database marketing agencies, announced the appointment of Vice President Pete Mehr, Ph.D., as chief strategy officer to its growing healthcare marketing practice, which launched earlier this year to provide data-driven marketing insight and strategy to leading healthcare and pharmaceutical clients.

31 Aug 2009

Merck undergoes restructuring after Schering-Plough merger

Richard T. Clark, chairman, president and chief executive officer of Merck & Co., Inc. (NYSE: MRK) today announced a new organizational structure and named top management and senior leaders for the new Merck effective upon completion of the merger of Merck & Co., Inc. and Schering-Plough Corporation. Mr. Clark was named CEO of the combined company when the merger agreement was signed in March.

31 Aug 2009

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Researchers today published promising results for a drug that could lead to a replacement for the very effective but difficult-to-use blood thinner Coumadin (sold generically as Warfarin), currently taken by millions of Americans to reduce their risk of stroke.

31 Aug 2009

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company is pleased to announce that the company has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.

31 Aug 2009

Takeda visits managed care professionals to promote its two new drugs

According to SDI, a leading healthcare market insight and analytics firm, in spring 2009, Takeda made more visits to managed care professionals than any other pharmaceutical manufacturer, accounting for almost 7% of contacts recorded in SDI’s Managed Care Pharmacy Executive and Managed Care Medical Director audits.

31 Aug 2009

Pharmaceuticals News and Research

BioClinica offers streamlined electronic transport solutions with the acquisition of CardioNow

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced

Biovail announces Phase III trial results for pimavanserin

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Six-month period financial results released by Cannasat Therapeutics

Cumberland Pharmaceuticals to discuss its recently approved FDA product at the UBS Conference

New gene therapy vector developed for transferring therapeutic DNA to a cell's nucleus

Chemists design polymer-coated nanorods for drug manufacturers

Managing costs for clinical trials is a big challenge

BioSyent's subsidiary BioSyent Pharma signs an exclusive product development agreement

FDA approves Hospira's six new vial presentations of heparin

New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

New chief strategy officer for Merkle

Merck undergoes restructuring after Schering-Plough merger

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Takeda visits managed care professionals to promote its two new drugs

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring